Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: Rapid depletion of white blood cells, platelets, and reticulocytes are hallmarks of hematopoietic injury of acute radiation syndrome (H-ARS) and, if left untreated, can lead to severe health consequences including death. While the granulocyte colony stimulating factors (G-CSF) filgrastim (Neupogen®), pegfilgrastim (Neulasta®), and sargramostim (Leukine®) are approved to increase survival in patients exposed to a myelosuppressive dose of radiation, no medical countermeasure is currently available for treatment of the thrombocytopenia that also results following radiation exposure. Romiplostim (Nplate®), a thrombopoietin receptor agonist, is the first FDA-approved thrombopoiesis-stimulating protein for the treatment of low platelet (PLT) counts in adults with chronic immune thrombocytopenia. Herein, we present the results of an analysis in mice of romiplostim as a medical countermeasure to improve survival and PLT recovery following acute radiation.Materials and methods: Male and female C57BL/6J mice (11 − 12 weeks of age, n = 21/sex/group) were total body irradiated (TBI) with 6.8 Gy X-rays that reduces 30-day survival to 30% (LD70/30). Vehicle, romiplostim, and/or pegfilgrastim were administered subcutaneously beginning 24 h after TBI for 1–5 days. Evaluation parameters included 30-day survival, pharmacokinetics, and hematology.Results: Full or maximal efficacy with an ∼40% increase in survival was achieved after a single 30 µg/kg dose of romiplostim. No further survival benefit was seen with higher (100 µg/kg) or more frequent dosing (3 or 5 once daily doses at 30 µg/kg) of romiplostim or combined treatment with pegfilgrastim. Pharmacodynamic analysis revealed that the platelet nadir was not as low and recovery was faster in the irradiated mice treated with romiplostim when compared with irradiated control animals (Day 8 versus 10 nadir; Day 22 versus 29 recovery to near baseline). Platelet volume also increased more rapidly after romiplostim injection. Kinetic profiles of other hematology parameters were similar between TBI romiplostim-treated and control mice. Peak serum levels of romiplostim in TBI mice occurred 4 − 24 h (Tmax) after injection with a t1/2 of ∼24 h. Cmax values were at ∼6 ng/ml after 30 µg/kg ± TBI and ∼200 ng/ml after 300 µg/kg. A 10-fold higher romiplostim dose increased the AUClast values by ∼35-fold.Conclusion: A single injection of romiplostim administered 24 h after TBI is a promising radiation medical countermeasure that dramatically increased survival, with or without pegfilgrastim, and hastened PLT recovery in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In those studies, a single subcutaneous dose of 30 μg/kg romiplostim twenty-four hours post-irradiation led to a 40% increase in 30-day survival at a TBI dose resulting in 70% lethality (LD 70/30 ).”
From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Bunin et al., 2020
In the citing paper
“The survival improvement was associated with an accelerated recovery from thrombocytopenia.”
From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Bunin et al., 2020
In the citing paper
“Further, the addition of pegfilgrastim to the treatment regimen did not provide further survival benefit to romiplostim alone (Bunin et al., 2020).”
From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Bunin et al., 2020
Citations
Cites
Waselenko, J. K., MacVittie, T. J., Blakely, W. F., Pesik, N., Wiley, A. L., Dickerson, W. E., Tsu, H., Confer, D. L., Coleman, C. N., Seed, T., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-12-200406150-00015 · Cited by 766 · cited 1×
“These three approved cytokines address post-radiation neutropenia (low neutrophil counts) and the increased risk of infection and febrile neutropenia (Waselenko et al. 2004; Singh et al. 2015) but do not address thrombocytopenia (low platelet counts) and excessive bleeding that also occurs in H-ARS.”
BackgroundThrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683 · cited 1×
“Romiplostim has no sequence homology to endogenous TPO thereby reducing the potential for neutralizing antibody production which halted the clinical development of earlier recombinant TPO mimetics (Li et al. 2001).”
BackgroundAnimal Models for Medical Countermeasures to Radiation Exposure
Williams, J. P., Brown, S. L., Georges, G. E., Hauer-Jensen, M., Hill, R. P., Huser, A. K., Kirsch, D. G., MacVittie, T. J., Mason, K. A., Medhora, M. M., et al. (2010) · Radiation Research · doi:10.1667/rr1880.1 · Cited by 423 · cited 3×
“Up to six mice were irradiated at a time on Day 1 with each irradiation session occurring between 7:15 and 11:15 am to minimize circadian effects (Williams et al. 2010; Plett et al. 2012).”
BackgroundMethodPharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand
WANG, B., NICHOL, J., & SULLIVAN, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.010 · Cited by 295 · cited 1×
“…exposed to myelosuppressive doses of radiation, the pharmacokinetics of romiplostim in irradiated animals should be compared with the already well characterized pharmacokinetics in non-irradiated animals and healthy human subjects (Wang et al. 2004; Wang et al. 2010; Krzyzanski et al. 2013).”
BackgroundAMG531 stimulates megakaryopoiesis in vitro by binding to Mpl
Broudy, V (2004) · Cytokine · doi:10.1016/j.cyto.2003.05.001 · Cited by 205
Acute Gastrointestinal Syndrome in High-Dose Irradiated Mice
Booth, C., Tudor, G., Tudor, J., Katz, B. P., & MacVittie, T. J. (2012) · Health Physics · doi:10.1097/hp.0b013e318266ee13 · Cited by 198 · cited 1×
“Thus, the difference in control group survival may be due to study-to-study variability and/or increased hydration from five daily doses of saline, both of which are known to be confounding variables in mouse ARS survival studies (Booth et al. 2012; Plett et al. 2012; Plett et al. 2015).”
BackgroundSingh, V. K., & Seed, T. M. (2017) · International Journal of Radiation Biology · doi:10.1080/09553002.2017.1332438 · Cited by 175
Establishing a Murine Model of the Hematopoietic Syndrome of the Acute Radiation Syndrome
Plett, P. A., Sampson, C. H., Chua, H. L., Joshi, M., Booth, C., Gough, A., Johnson, C. S., Katz, B. P., Farese, A. M., Parker, J., et al. (2012) · Health Physics · doi:10.1097/hp.0b013e3182667309 · Cited by 150 · cited 6×
“…levels including relatively low levels of radiation (Williams et al. 2010), (2) TBI mice become more susceptible to lethality following blood collection (Plett et al. 2012), and (3) we wanted to have sufficient numbers of surviving mice at the later post-dose time points for a robust analysis.”
BackgroundMethodResultInfluentialPegfilgrastim improves survival of lethally irradiated nonhuman primates
Hankey, K. G., Farese, A. M., Blaauw, E. C., Gibbs, A. M., Smith, C. P., Katz, B. P., Tong, Y., Prado, K. L., & MacVittie, T. J. (2015) · Radiation Research · doi:10.1667/rr13940.1 · Cited by 129 · cited 1×
“Pegfilgrastim was tested at 300 mg/kg as reported in other studies (Farese et al. 2012; Chua et al. 2014; Hankey et al. 2015).”
ResultSingh, V. K., Newman, V. L., & Seed, T. M. (2015) · Cytokine · doi:10.1016/j.cyto.2014.08.003 · Cited by 121 · cited 1×
“These three approved cytokines address post-radiation neutropenia (low neutrophil counts) and the increased risk of infection and febrile neutropenia (Waselenko et al. 2004; Singh et al. 2015) but do not address thrombocytopenia (low platelet counts) and excessive bleeding that also occurs in H-ARS.”
Background
Research works printed but not linked: 2
- Levin J, 1982, Blood, 60, 989
- U.S. Department of Health and Human Services Press Office. 2016. HHS enhances nation's health preparedness for radiological threats. [updated October 6, 2016
Cited by
Singh, V. K., & Seed, T. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1702968 · Cited by 125
“A single intraperitoneal (ip) administration of Romiplostim initiated 2 h after irradiation and continued for 3 or 5 days (daily administration, 50 µg/kg) provided 100% survival in C57BL/6J mice exposed to a lethal dose (7 Gy, dose rate 0.9 Gy/min) of Cesium-137 (137Cs) γ-rays [70].”
BackgroundInfluentialA Review of Romiplostim Mechanism of Action and Clinical Applicability
Bussel, J. B., Soff, G. A., Balduzzi, A., Cooper, N., Lawrence, T. C., & Semple, J. W. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s299591 · Cited by 107
Gavriatopoulou, M., Chari, A., Chen, C. I., Bahlis, N. J., Vogl, D. T., Jakubowiak, A. J., Dingli, D., Cornell, R. F., Hofmeister, C. C., Siegel, D. S. D., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0756-6 · Cited by 99
Singh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry
Obrador, E., Palmer, R. S., Villaescusa, J. I., Gallego, E., Pellicer, B., Estrela, J. M., & Montoro, A. (2022) · Antioxidants · doi:10.3390/antiox11061098 · Cited by 88
“Furthermore, a single dose of Nplate® (30 μg/kg) enhanced the survival to 40% [267]; combined with G-CSF and EPO, it increased survival to 100% (0% survival in controls 30 days after exposure), recovering hematological parameters to the levels of non-irradiated mice [268].”
Background
Metadata
- Authors
- Bunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y.
- Affiliations
- SRI International (US)
- Amgen (United States) (US)
- Corresponding author
- Bunin, Deborah I.
- Venue
- International Journal of Radiation Biology
- Publisher
- Informa UK Limited
- Published
- 2019-04-29
- Volume
- 96
- Issue
- 1
- Pages
- 145-154
- ISSN
- 0955-3002 (ISSN-L)
- 1362-3095
- OpenAlex
- W2941607887
- Semantic Scholar
- ac624f09f33e03dabde6ef917fa61bee85376501
- Cited by
- 60
- References
- 24
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 9 · 2020: 7 · 2019: 2
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Radiation Biology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institue of Allergy and Infectious Diseases, National Institues of Health, Dept. of Health and Human Services (HHSN272201500013I)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- romiplostim, radiation sickness, radiation countermeasures, thrombopoietin receptor agonists, thrombocytopenia, platelet recovery, total body irradiation, pegfilgrastim, hematopoietic damage, survival, pharmacokinetics, pharmacodynamics, platelet volume, mice
- MeSH terms
- Filgrastim, Medical Countermeasures, Animals, Blood Platelets, Dose-Response Relationship, Drug, Drug Interactions, Female, Male, Mice, Inbred C57BL, Platelet Count, Polyethylene Glycols, Receptors, Fc, Recombinant Fusion Proteins, Thrombopoietin, X-Rays, Survival Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. https://app.cochat.ai/papers/10.1080/09553002.2019.1605465
- The paper
- Bunin, D. I., Bakke, J., Green, C. E., Javitz, H. S., Fielden, M., & Chang, P. Y. (2020). Romiplostim (Nplate®) as an effective radiation countermeasure to improve survival and platelet recovery in mice. International Journal of Radiation Biology. https://doi.org/10.1080/09553002.2019.1605465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.